Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HL-TOF
- Development stage
- Unknown
- Lead developer
- Hanlim Pharm. Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HL-TOF is a generic formulation of tofacitinib developed by Hanlim Pharm. Co., Ltd. for the treatment of moderate to severe rheumatoid arthritis. It is formulated as tofacitinib freebase, distinguishing it from the reference product Xeljanz, which contains tofacitinib citrate. As a small molecule Janus kinase (JAK) inhibitor, HL-TOF targets JAK1, JAK2, and JAK3, and to a lesser extent TYK2, thereby inhibiting the signaling of multiple cytokines involved in the inflammatory cascade. The drug has undergone Phase 1 clinical evaluation in healthy volunteers to establish bioequivalence, safety, and pharmacokinetic profiles comparable to the branded reference product.
- Other names
- tofacitinib freebase
02
Targets
Beyond the preview
Go deeper on HL-TOF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HL-TOF.